Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ben Weintraub"'
Autor:
Iffat Anjum, Jessica Sokal, Hafiza Ramzah Rehman, Ben Weintraub, Ethan Leba, William Enck, Cristina Nita-Rotaru, Bradley Reaves
Publikováno v:
Proceedings of the 28th ACM Symposium on Access Control Models and Technologies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c137f88a0e0237b7cc2e6a54d5dd808
https://doi.org/10.1145/3589608.3593836
https://doi.org/10.1145/3589608.3593836
Automated Attack Synthesis by Extracting Finite State Machines from Protocol Specification Documents
Automated attack discovery techniques, such as attacker synthesis or model-based fuzzing, provide powerful ways to ensure network protocols operate correctly and securely. Such techniques, in general, require a formal representation of the protocol,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b3621790f46489dc9a03b773fe07691
http://arxiv.org/abs/2202.09470
http://arxiv.org/abs/2202.09470
Publikováno v:
EuroS&P Workshops
Payment channel networks (PCN) enable scalable blockchain transactions without fundamentally changing the underlying distributed ledger algorithm. However, routing a payment via multiple channels in a PCN requires locking collateral for potentially l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8051d6796b98acfb8583ab5994e10266
http://arxiv.org/abs/2007.09047
http://arxiv.org/abs/2007.09047
Autor:
Ben Weintraub
Publikováno v:
BioDrugs. 25:135-138
New data presented at the 2010 meeting of the American Society of Hematology (ASH), at the 33rd San Antonio Breast Cancer Symposium (SABCS), and released by Amgen are beginning to define the anti-tumor effects of Amgen's denosumab (Xgeva™) and Nova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf8a1eeea06486469dff3502dbf71b45
https://doi.org/10.2165/11590730-000000000-00000
https://doi.org/10.2165/11590730-000000000-00000
Autor:
Ben Weintraub
Publikováno v:
BioDrugs. 25:203-205
Speaking for the inThought Expert Discussion Series in February, Dr George Tsokos mirrored the opinion of many lupus thought leaders: Human Genome Sciences (HGS) and GlaxoSmithKline's (GSK) belimumab (Benlysta®) was likely to be approved by the US F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dd045844dc273294567ddf9df94f89c
https://doi.org/10.2165/11591850-000000000-00000
https://doi.org/10.2165/11591850-000000000-00000